Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 12, 2023 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors

Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standards of care versus standards of care alone in subjects with advanced solid tumors...
September 06, 2023 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma

BASKING RIDGE, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
September 05, 2023 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces Participation in Upcoming Conferences in September

BASKING RIDGE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
August 14, 2023 16:05 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Cash runway projected into first quarter 2026 based on capital conservation measures implemented without impact to clinical development pipeline Technology transfer agreement executed for Company’s...
August 08, 2023 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma

BASKING RIDGE, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
August 07, 2023 08:30 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time

BASKING RIDGE, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
July 11, 2023 08:30 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors

BASKING RIDGE, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
June 12, 2023 08:30 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference

BASKING RIDGE, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
May 24, 2023 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1

Target enrollment increased to 155 subjects with the addition of a cohort testing a second dose of LSTA1 Results to be used to explore possible conditional approvals globally Futility analysis...
May 09, 2023 16:05 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Conference call scheduled for today at 4:30 p.m. Eastern time BASKING RIDGE, N. J., May 09, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a...